92.85 0.00 (0.00%)
After hours: 4:46PM EST
|Bid||92.82 x 1000|
|Ask||92.50 x 800|
|Day's Range||92.79 - 95.08|
|52 Week Range||57.00 - 96.79|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||49.63|
|Earnings Date||Feb 12, 2020 - Feb 17, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||94.69|
Incyte cleared an 89.40 buy point. Incyte has been running up since late September, especially after the cancer-focused biotech reported earnings doubled in late October.
The stock market regained its footing after an up-and-down morning with investors facing competing trade narratives from the U.S. government.
While the stock market tries to close 2019 near new all-time highs, Paycom, Lululemon, ServiceNow, RH and 29 others are all up big year to date.
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the J. P. Morgan 38th Annual Healthcare Conference on Monday, January 13, 2020 at 8:30 am (PST) in San Francisco.
Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing […]
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
For innovative drugmakers, product cycles are everything. That's why investors are so intrigued with fast-growing Incyte stock right now.
The Dow Jones Industrial Average enjoyed a bullish month, as did small-cap and key growth stocks. Will these six names jam in December?
The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.
The S&P 500 Health Care index has underperformed the market in 2019, up 15.2% to the S&P 500’s 25.8%. Shares of Edwards Lifesciences, which sells heart valves and monitoring equipment, are up 60.8% so far this year. In August, the Food and Drug Administration approved two Edwards devices, SAPIEN 3 and SAPIEN 3 Ultra, for a broader set of patients, following the release of positive trial results earlier in the year.
Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma
Discover 12 stocks, including Kirkland Lake Gold, InMode, Incyte, and Inphi expecting earnings growth above 50% this year.
The Dow Jones Industrial Average has lagged in a bullish fourth quarter as this index ETF races 2% higher. Growth stocks show solid post-breakout gains.
Incyte announces that numerous abstracts, including data from its clinical development programs for ruxolitinib , itacitinib and ponatinib will be presented at the upcoming American Society of Hematology Annual Meeting 2019 in Orlando, Florida from December 7-10, 2019.
Trading pro Anne-Marie Baiynd shares why Dow Jones giants Boeing and Caterpillar could offer potential gains — and what buy points she's using.
Merck's (MRK) Keytruda gets approval in Europe to treat first-line head/neck cancer based on data from the phase III KEYNOTE-048 study.
Incyte stock is the IBD Stock Of The Day amid a breakout and enthusiasm for the biotech company's diversifying pipeline and $2 billion war chest. Incyte makes Jakafi, a blockbuster drug.